Ralliant (NYSE:RAL) Director Kevin Bryant Acquires 1,250 Shares

Ralliant Corporation (NYSE:RAL) Director Kevin Bryant acquired 1,250 shares of the business’s stock in a transaction that occurred on Friday, February 6th. The stock was bought at an average cost of $39.97 per share, for a total transaction of $49,962.50. Following the completion of the purchase, the director directly owned 4,653 shares in the company, valued at $185,980.41. This represents a 36.73% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Ralliant Stock Up 2.9%

Shares of Ralliant stock opened at $39.50 on Monday. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $57.02. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. The stock has a 50 day moving average price of $51.52 and a two-hundred day moving average price of $46.72. The stock has a market capitalization of $4.46 billion and a P/E ratio of 31.10.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million during the quarter, compared to analyst estimates of $543.04 million. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s dividend payout ratio (DPR) is currently 15.75%.

Institutional Trading of Ralliant

Institutional investors have recently made changes to their positions in the business. Pinnbrook Capital Management LP acquired a new position in Ralliant in the fourth quarter worth about $7,878,000. Covestor Ltd raised its holdings in shares of Ralliant by 4,096.7% in the 4th quarter. Covestor Ltd now owns 11,583 shares of the company’s stock worth $590,000 after buying an additional 11,307 shares in the last quarter. Gabelli Funds LLC raised its holdings in shares of Ralliant by 11.9% in the 4th quarter. Gabelli Funds LLC now owns 29,836 shares of the company’s stock worth $1,519,000 after buying an additional 3,177 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Ralliant by 3.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 218,251 shares of the company’s stock worth $11,111,000 after buying an additional 8,206 shares during the period. Finally, Allworth Financial LP boosted its stake in Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares in the last quarter.

Analysts Set New Price Targets

Several analysts recently weighed in on RAL shares. Royal Bank Of Canada decreased their target price on Ralliant from $52.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday. Truist Financial reduced their price objective on Ralliant from $62.00 to $49.00 and set a “buy” rating for the company in a research report on Friday. Oppenheimer lowered their price objective on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Friday. Morgan Stanley reiterated an “overweight” rating and set a $45.00 target price on shares of Ralliant in a research note on Friday. Finally, Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Friday. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Ralliant has a consensus rating of “Moderate Buy” and a consensus price target of $51.30.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.